Examples of 'ceritinib' in a sentence
Meaning of "ceritinib"
Certinib is an adjective used to describe something related to the drug ceritinib, which is a medication used in cancer treatment, particularly for non-small cell lung cancer
Show more definitions
- A particular drug for the treatment of lung cancer.
How to use "ceritinib" in a sentence
Basic
Advanced
ceritinib
Zykadia contains the active substance ceritinib.
Ceritinib should be taken on an empty stomach.
The absolute bioavailability of ceritinib has not been determined.
Ceritinib must be taken with food.
Agents that may increase ceritinib plasma concentrations.
Carcinogenicity studies have not been performed with ceritinib.
Agents that may decrease ceritinib plasma concentrations.
Agents whose plasma concentration may be altered by ceritinib.
The bioavailability of ceritinib is increased in the presence of food.
Monitor for ADRs related to ceritinib.
Systemic exposure to ceritinib is increased when administered with food.
Caution should be exercised in administering ceritinib with ritonavir.
Refer to the ceritinib SmPC for dosage adjustment recommendations.
None of these events led to discontinuation of ceritinib treatment.
Systemic exposure of ceritinib was increased when administered with food.
See also
Zykadia is a cancer medicine that contains the active substance ceritinib.
The in vitro apparent passive permeability of ceritinib was determined to be low.
Ceritinib is a selective and potent inhibitor of anaplastic lymphoma kinase ALK.
The active substance of Zykadia is ceritinib.
Administering ceritinib with Kaletra.
QTc prolongation has been observed in patients treated with ceritinib.
Based on available data, ceritinib is eliminated primarily via the liver.
Caution should be exercised in administering ceritinib with Kaletra.
Ceritinib demonstrates pH-dependent solubility and becomes poorly soluble as pH increases in vitro.
Caution should be exercised in administering ceritinib with Norvir.
Ceritinib Serum concentrations may be increased due to CYP3A and P-gp inhibition by ritonavir.
What Zykadia contains The active substance of Zykadia is ceritinib.
However, based on available data, ceritinib elimination via the kidney is negligible.
Cases of hepatotoxicity occurred in less than 1 % of patients receiving ceritinib in clinical studies.
Ceritinib should be discontinued in patients unable to tolerate 300 mg daily.
Therefore, hepatic impairment may increase ceritinib plasma concentrations.
Co-administration of ceritinib with strong CYP3A/P-gp inducers decreases ceritinib plasma concentrations.
Elevations of lipase and / or amylase have occurred in patients treated with ceritinib in clinical studies.
Ceritinib is not recommended in patients with moderate to severe hepatic impairment see section 5.2.
Formal non-clinical studies on the potential effects of ceritinib on fertility have not been conducted.
In clinical studies, QT prolongation was observed with ceritinib.
Caution should be exercised in administering ceritinib with Lopinavir / Ritonavir Mylan.
Ceritinib is not recommended in patients with moderate or severe hepatic impairment see section 4.2.
Addition of a thiol group to O-dealkylated ceritinib was also observed.
Ceritinib has been classified in vivo as a weak CYP2C9 inhibitor.
Cases of hepatotoxicity occurred in 1.1 % of patients receiving ceritinib in clinical studies.
A pharmacokinetic analysis suggested that ceritinib causes concentration-dependent increases in QTc see section 4.4.
Cases of pancreatitis have been reported in patients treated with ceritinib see section 4.8.
Based on in vitro data, ceritinib is a substrate of the efflux transporter P-glycoprotein P-gp.
Of these patients 81 received ceritinib.
Alectinib or ceritinib as the first ALK tyrosine kinase inhibitor ( TKI ) therapy ; or.
Increases to grade 3 or 4 ALT elevations were observed in 25 % of patients receiving ceritinib.
Ceritinib is not recommended in these patients see section 4.2.
A Alectinib, brigatinib, or ceritinib.
Ceritinib is not recommended for patients with moderate to severe hepatic impairment see sections 4.2 and 4.8.
